← All trials
NCT05693129
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 30, 2023
- Primary completion
- Sep 30, 2025
- Completion date
- Nov 28, 2025
- First posted
- Jan 20, 2023
- Last posted
- Dec 21, 2023
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pharming GroupLead sponsor
- CMIC Co, Ltd. JapanCollaborator
- LabCorpCollaborator
- Aixial GroupCollaborator
- FortreaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.